Sequana Medical NV (Euronext Brussels: SEQUA), a leader in the treatment of fluid overload in liver disease, heart failure, and cancer, is cordially inviting all shareholders to attend its upcoming Extraordinary General Meeting of Shareholders on Friday, 10 February 2023. This is a chance to get an inside look at a pioneering medical company and its ambitious plans for the future. Don’t miss out on this exciting opportunity!
At the upcoming meeting, the Company is set to make some exciting decisions, such as approving the appointment of Douglas Kohrs and Alexandra Taylor Clyde as independent non-executive directors, approving certain amendments to the Company’s remuneration policy, and issuing “Kreos Subscription Rights” (in the form of subscription rights). This meeting promises to be an important one for the Company’s future and all involved.
We invite all our shareholders to join us for the Extraordinary General Meeting of Shareholders at our registered offices in Ghent, starting at 09:00 am CEST. Don’t miss this chance to stay up to date on all our company’s progress – full details of the agenda and proposed resolutions can be found on our Sequana Medical website.
In light of the COVID-19 pandemic, the Board of Directors recommends that shareholders make use of their right to vote through voting by mail or by proxy to the Chair of the Board of Directors, to ensure the smooth running of the Extraordinary General Meeting of Shareholders. This is a great way to keep everyone safe and secure, while still making sure that everyone’s voice is heard.
The Company will grant access to the meeting to security holders, proxy holders and other persons in accordance with the guidelines of the relevant authorities and with safety and health in mind. We want to make sure that everyone who wishes to attend is able to do so in a safe and secure environment.
The Company invites all holders of its securities to communicate with the Company regarding the Extraordinary General Meeting of Shareholders via e-mail. To do so, please utilize the following e-mail address.
About Sequana Medical
Fluid overload is a serious clinical complication that affects many patients suffering from liver disease, heart failure and cancer. With up to 15 liters of excess fluid, patients experience increased mortality, repeated hospitalizations, severe pain and restricted mobility that significantly impacts their daily lives. Unfortunately, diuretics are often no longer effective or tolerable for these patients, leaving them with limited treatment options and poor clinical outcomes. Seeking to provide innovative solutions for this diuretic-resistant patient population, Sequana Medical NV is pioneering treatments for fluid overload. With their help, patients can benefit from improved quality of life and cost savings.
Sequana Medical’s alfapump® and DSR® platforms are revolutionizing the treatment of diuretic-resistant fluid overload, providing major clinical and quality of life benefits for patients, as well as reducing costs for healthcare systems. The Company’s POSEIDON study of the alfapump in recurrent or refractory ascites due to liver cirrhosis has reported positive primary endpoint data, paving the way for the submission of a Pre-Market Approval (PMA) application to the FDA in H2 2023. As for the DSR platform, having demonstrated its potential as a disease-modifying drug program for the treatment of heart failure, a US multi-centered randomized controlled Phase 1/2a clinical study of DSR 2.0, known as MOJAVE, is set to begin in H1 2023.
Headquartered in Ghent, Belgium, Sequana Medical is a publicly-traded company listed on the Euronext Brussels exchange under the ticker SEQUA.BR. This innovative company is making waves in the medical field by providing solutions for treating serious medical conditions.
Important Regulatory Disclaimers
The alfapump® system is currently under clinical investigation in the United States and Canada for adult patients with refractory or recurrent ascites due to cirrhosis. This is known as the POSEIDON Study and more information can be found at www.poseidonstudy.com. On the other hand, DSR® therapy is still under development and is yet to be approved for clinical research in the United States or Canada. There is no link between DSR therapy and the ongoing investigations regarding the alfapump system in Europe, the United States or Canada.
The future holds great potential for Sequana Medical, but with it comes risk and uncertainty. We make no guarantees of future performance, and any predictions, estimates or other information in this press release that may be considered forward-looking statements should not be relied upon. We will continue to update and revise these forward-looking statements as necessary, as required by law or regulation. We are optimistic about what the future holds, and remain committed to making the most of it.